The DRAKO study, a 24-month prospective observational multi-center cohort study, evaluated standard-of-care intravitreal aflibercept (IVT-AFL) treatment for diabetic macular edema (DMO) in the UK. The study analyzed 12-month outcomes for patients with prior anti-VEGF treatment (C2) and 2-year outcomes for anti-VEGF-naïve (C1) and C2 patients. Results showed IVT-AFL was effective, with improvements in BCVA and CST, even with relatively low injection numbers. High baseline visual and quality-of-life scores were maintained, indicating the effectiveness of IVT-AFL in real-world UK clinical practice.
Publisher
Eye
Published On
Mar 20, 2023
Authors
Sobha Sivaprasad, Faruque Ghanchi, Simon P. Kelly, Ajay Kotagiri, James Talks, Peter Scanlon, Hellen McGoey, Andrew Nolan, Moneeb Saddiq, Jackie Napier
Tags
DRAKO study
diabetic macular edema
intravitreal aflibercept
anti-VEGF treatment
clinical outcomes
BCVA
real-world effectiveness
Related Publications
Explore these studies to deepen your understanding of the subject.